E W Muilwijk1, J A Schouten2, H J van Leeuwen3, A R H van Zanten4, D W de Lange5, A Colbers6, P E Verweij7, D M Burger8, P Pickkers9, R J M Brüggemann8. 1. Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands eline.muilwijk@radboudumc.nl. 2. Department of Intensive Care, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 3. Department of Intensive Care, Rijnstate Hospital, Arnhem, The Netherlands. 4. Department of Intensive Care, Gelderse Vallei Hospital, Ede, The Netherlands. 5. Department of Intensive Care and National Poison Information Center, University Medical Center Utrecht, Utrecht, The Netherlands. 6. Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands. 7. Department of Medical Microbiology, Radboud university medical center, Nijmegen, The Netherlands Radboud Institute for Health Sciences, Nijmegen, The Netherlands. 8. Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands Radboud Institute for Health Sciences, Nijmegen, The Netherlands. 9. Department of Intensive Care, Radboud university medical center, Nijmegen, The Netherlands.
Abstract
OBJECTIVES: Caspofungin is used for treatment of invasive fungal infections. As the pharmacokinetics (PK) of antimicrobial agents in critically ill patients can be highly variable, we set out to explore caspofungin PK in ICU patients. METHODS: ICU patients receiving caspofungin were eligible. Patients received a loading dose of 70 mg followed by 50 mg daily (70 mg if body weight >80 kg); they were evaluable upon completion of the first PK curve at day 3. Additionally, daily trough samples were taken and a second PK curve was recorded at day 7. PK analysis was performed using a standard two-stage approach. RESULTS: Twenty-one patients were evaluable. Median (range) age and body weight were 71 (45-80) years and 75 (50-99) kg. PK sampling on day 3 (n = 21) resulted in the following median (IQR) parameters: AUC0-24 88.7 (72.2-97.5) mg·h/L; Cmin 2.15 (1.40-2.48) mg/L; Cmax 7.51 (6.05-8.17) mg/L; V 7.72 (6.12-9.01) L; and CL 0.57 (0.54-0.77) L/h. PK sampling on day 7 (n = 13) resulted in AUC0-24 107.2 (90.4-125.3) mg·h/L, Cmin 2.55 (1.82-3.08) mg/L, Cmax 8.65 (7.16-9.34) mg/L, V 7.03 (5.51-7.73) L and CL 0.54 (0.44-0.60) L/h. We did not identify any covariates significantly affecting caspofungin PK in ICU patients (e.g. body weight, albumin, liver function). Caspofungin was well tolerated and no unexpected side effects were observed. CONCLUSIONS: Caspofungin PK in ICU patients showed limited intraindividual and moderate interindividual variability, and caspofungin was well tolerated. A standard two-stage approach did not reveal significant covariates. Our study showed similar caspofungin PK parameters in ICU patients compared with non-critically ill patients.
OBJECTIVES:Caspofungin is used for treatment of invasive fungal infections. As the pharmacokinetics (PK) of antimicrobial agents in critically illpatients can be highly variable, we set out to explore caspofungin PK in ICU patients. METHODS: ICU patients receiving caspofungin were eligible. Patients received a loading dose of 70 mg followed by 50 mg daily (70 mg if body weight >80 kg); they were evaluable upon completion of the first PK curve at day 3. Additionally, daily trough samples were taken and a second PK curve was recorded at day 7. PK analysis was performed using a standard two-stage approach. RESULTS: Twenty-one patients were evaluable. Median (range) age and body weight were 71 (45-80) years and 75 (50-99) kg. PK sampling on day 3 (n = 21) resulted in the following median (IQR) parameters: AUC0-24 88.7 (72.2-97.5) mg·h/L; Cmin 2.15 (1.40-2.48) mg/L; Cmax 7.51 (6.05-8.17) mg/L; V 7.72 (6.12-9.01) L; and CL 0.57 (0.54-0.77) L/h. PK sampling on day 7 (n = 13) resulted in AUC0-24 107.2 (90.4-125.3) mg·h/L, Cmin 2.55 (1.82-3.08) mg/L, Cmax 8.65 (7.16-9.34) mg/L, V 7.03 (5.51-7.73) L and CL 0.54 (0.44-0.60) L/h. We did not identify any covariates significantly affecting caspofungin PK in ICU patients (e.g. body weight, albumin, liver function). Caspofungin was well tolerated and no unexpected side effects were observed. CONCLUSIONS:Caspofungin PK in ICU patients showed limited intraindividual and moderate interindividual variability, and caspofungin was well tolerated. A standard two-stage approach did not reveal significant covariates. Our study showed similar caspofungin PK parameters in ICU patients compared with non-critically illpatients.
Authors: S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Kim C M van der Elst; Anette Veringa; Jan G Zijlstra; Albertus Beishuizen; Rob Klont; Petra Brummelhuis-Visser; Donald R A Uges; Daan J Touw; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: R J M Brüggemann; V Middel-Baars; D W de Lange; A Colbers; A R J Girbes; P Pickkers; E L Swart Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Vincent J Lempers; Jeroen A Schouten; Nicole G Hunfeld; Angela Colbers; Henk J van Leeuwen; David M Burger; Paul E Verweij; Peter Pickkers; Roger J Brüggemann Journal: Antimicrob Agents Chemother Date: 2015-05-11 Impact factor: 5.191
Authors: Claire Roger; Steven C Wallis; Laurent Muller; Gilbert Saissi; Jeffrey Lipman; Roger J Brüggemann; Jean-Yves Lefrant; Jason A Roberts Journal: Clin Pharmacokinet Date: 2017-09 Impact factor: 6.447
Authors: Nicholas D Beyda; Jonathan Amadio; Jose R Rodriguez; Karen Malinowski; Kevin W Garey; Audrey Wanger; Luis Ostrosky-Zeichner Journal: J Clin Microbiol Date: 2018-07-26 Impact factor: 5.948